ReviewMalaria journal2019
A case of Plasmodium malariae recurrence: recrudescence or reinfection?
Review in Malaria journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Tropism ofEmerging microbes & infections · 2026Article
- Unraveling the origins and features of long-latency Plasmodium malariae infections: a comprehensive epidemiological, clinical, and genetic study of seven cases in Guangdong Province (2014-2022).BMC infectious diseases · 2026Article
- Plasmodium malariae is an overlooked malaria parasite with emerging challenges.Communications medicine · 2026Review
- Congenital infection with Plasmodium malariae: a rare case of intrauterine transmission in Germany.Malaria journal · 2025Article
- Leveraging genomic insights from the neglected malaria parasites P. malariae and P. ovale using selective whole genome amplification (SWGA) approach.BMC genomics · 2025Article
- Non-falciparum malaria infections in Uganda, does it matter? A review of the published literature.Malaria journal · 2024Review
- Dataset of 16S rRNA and alkB genes in hydrocarbon polluted soils of Kuwait as revealed by Pyrosequencing.Data in brief · 2022Article
- Article
- Article
- Antibody Profile Comparison against MSP1 Antigens of MultiplePathogens (Basel, Switzerland) · 2021Article
- Recent Molecular Assessment of Plasmodium vivax and Plasmodium falciparum Asymptomatic Infections in Botswana.The American journal of tropical medicine and hygiene · 2021Article
- Safety and Efficacy of Tafenoquine forTherapeutics and clinical risk management · 2021Article
- Recurrence ofOpen forum infectious diseases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlasmodium malariae is the most neglected of the six human malaria species and it is still unknown which is the mechanism underlying the long latency of this Plasmodium. CASE PRESENTATION: A case of PCR-confirmed P. malariae recurrence in a 52-year old Italian man was observed 5 months after a primary attack. In the interval between the two observed episodes of malaria the patient denied any further stay in endemic areas except for a visit to Libya, a country considered malaria-free. Genomic DNA of the P. malariae strain using five microsatellites (PM2, PM9, PM11, PM25, PM34) and the antigen marker of circumsporozoite (csp) was amplified and sequenced. Analysis of polymorphisms of the P. malariae csp central repeat region showed differences between the strains responsible of the first and second episode of malaria. A difference in the allele size was also observed for the sequence analysis of PM2 microsatellites.
conclusionsPlasmodium malariae is a challenging human malaria parasite and even with the use of molecular techniques the pathogenesis of recurrent episodes cannot be precisely explained.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.